Toripalimab for limited-stage small cell lung cancer after chemoradiation
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding toripalimab (an immunotherapy) or toripalimab plus another immunotherapy (tifcemalimab) after standard chemoradiation can help prevent small cell lung cancer from coming back. It is for people with limited-stage disease who have finished initial treatment without the cancer growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have limited-stage small cell lung cancer that was treated with 4 cycles of chemo plus radiation.
- You finished your last chemotherapy dose within the last 42 days.
- Your cancer is stable, smaller, or gone after chemoradiation (no growth).
- You are at least 18 years old and able to perform daily activities with little help (ECOG 0 or 1).
- You do not have active autoimmune disease, HIV, hepatitis B or C, or other serious lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining standard chemotherapy with radiation (chemoradiotherapy) plus two additional drugs, toripalimab and surufatinib, for people with limited-stage small cell lung cancer. The goal is to see if this combination improves outcomes.
This trial tests whether adding two drugs (adebrelimab and apatinib) after standard chemoradiation can help prevent cancer from coming back in people with limited-stage small cell lung cancer. It is for patients whose cancer did not grow after chemoradiation.
This trial tests whether taking tislelizumab plus nintedanib after initial radiation and chemotherapy can help keep limited-stage small cell lung cancer from coming back. It is for people who have finished induction treatment and are in good overall health.
This trial tests a treatment plan that combines a short course of radiation with chemotherapy and an immunotherapy drug (adebrelimab). It is for people with limited-stage small cell lung cancer who haven't had treatment yet.
This study tests a combination of two drugs (BL0020 and Toripalimab) in patients whose small cell lung cancer has come back after initial chemotherapy treatment. The goal is to see if this combination is safe and can help control the cancer.
This trial tests whether a combination of toripalimab (an immunotherapy drug) and chemotherapy can help prevent small cell lung cancer from coming back after surgery. It is for people who had an unexpected finding of small cell lung cancer after their tumor was removed.
Hear when a new Limited-stage Small Cell Lung Cancer (LS-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.